Acorda Therapeutics (NASDAQ:ACOR) PT Lowered to $12.00

Acorda Therapeutics (NASDAQ:ACOR) had its price objective decreased by Cantor Fitzgerald from $20.00 to $12.00 in a research note published on Friday, The Fly reports. Cantor Fitzgerald currently has a neutral rating on the biopharmaceutical company’s stock.

ACOR has been the subject of several other reports. JPMorgan Chase & Co. reiterated a hold rating and set a $18.00 target price on shares of Acorda Therapeutics in a report on Tuesday, May 7th. BidaskClub lowered shares of Acorda Therapeutics from a sell rating to a strong sell rating in a report on Tuesday, July 9th. Wedbush started coverage on shares of Acorda Therapeutics in a report on Wednesday, May 22nd. They set a neutral rating and a $12.00 target price for the company. ValuEngine upgraded shares of Acorda Therapeutics from a sell rating to a hold rating in a report on Tuesday, July 2nd. Finally, Zacks Investment Research upgraded shares of Acorda Therapeutics from a hold rating to a buy rating and set a $8.25 target price for the company in a report on Wednesday, July 3rd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The company has an average rating of Hold and an average target price of $18.23.

Shares of ACOR stock traded down $2.92 during trading hours on Friday, hitting $3.15. 355,426 shares of the company’s stock traded hands, compared to its average volume of 730,283. The stock has a fifty day moving average price of $7.16. Acorda Therapeutics has a 12-month low of $6.03 and a 12-month high of $29.75. The firm has a market cap of $292.15 million, a PE ratio of 1.73 and a beta of 1.15. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.97 and a current ratio of 4.30.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.18) by $0.53. Acorda Therapeutics had a negative net margin of 1.40% and a positive return on equity of 9.34%. The firm had revenue of $50.05 million during the quarter, compared to analyst estimates of $28.83 million. During the same period last year, the business earned $1.40 earnings per share. The business’s revenue was down 67.4% on a year-over-year basis. On average, equities research analysts forecast that Acorda Therapeutics will post -4.01 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Financial Gravity Wealth Inc. bought a new stake in shares of Acorda Therapeutics during the first quarter valued at approximately $44,000. KBC Group NV bought a new stake in shares of Acorda Therapeutics during the second quarter valued at approximately $31,000. Oppenheimer Asset Management Inc. increased its position in shares of Acorda Therapeutics by 45.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 4,106 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,289 shares in the last quarter. Piedmont Investment Advisors Inc. bought a new stake in shares of Acorda Therapeutics during the first quarter valued at approximately $134,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Acorda Therapeutics by 869.8% during the first quarter. BNP Paribas Arbitrage SA now owns 10,241 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 9,185 shares in the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Featured Story: What are the FAANG Stocks?

The Fly

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.